Clinical guideline
Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer
ESMO Open · 2025
Studies and guidelines: Ovarian cancer
25 items with a structured summary · Ovarian cancer: the complete guide
Clinical guideline
Staging classification for cancer of the ovary, fallopian tube, and peritoneum
Intl J Gynecology & Obste · 2013
Clinical trial · Phase 3
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
Lancet · 2026
18.2 months vs 14.0 monthsMedian overall survival (PD-L1 CPS ≥1)
Review article
Transforming treatment paradigms: Focus on personalized medicine for high‐grade serous ovarian cancer
CA A Cancer J Clinicians · 2025
About 70%Share of HGSOC among all ovarian cancer cases
Clinical trial · Phase 3
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial
Lancet Oncol · 2023
44.9 months vs 33.3 monthsMedian overall survival
Clinical trial · Phase 3
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
Annals of Oncology · 2023
61.7 vs 61.9 monthsMedian follow-up (olaparib vs placebo)
Clinical trial · Phase 3
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
JCO · 2023
0.55 (95% CI 0.40 to 0.76)Hazard ratio for overall survival
Clinical trial
Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
The Lancet · 2021
522 (1.0%) in the MMS group, 517 (1.0%) in the USS group and 1016 (1.0%) in the no-screening groupWomen diagnosed with tubal or ovarian cancer (median follow-up 16.3 years)
Clinical trial · Phase 3
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer
N Engl J Med · 2021
53.7 vs 46.0 monthsMedian overall survival
Clinical trial · Phase 3
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
N Engl J Med · 2019
65.5 (lymphadenectomy) vs 69.2 monthsMedian overall survival
Review article
Epithelial ovarian cancer
The Lancet · 2019
Clinical trial · Phase 3
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
N Engl J Med · 2019
22.1 vs 16.6 monthsMedian PFS (whole population)
Clinical trial · Phase 3
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology · 2017
19.1 months (95% CI 16.3 to 25.7) vs 5.5 months (5.2 to 5.8)Median progression-free survival (investigator-assessed)
Clinical trial · Phase 3
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
JCO · 2014
0.48 (95% CI 0.38 to 0.60)Progression-free survival (HR)
Clinical trial · Phase 3
A phase 3 trial of bevacizumab in ovarian cancer
N Engl J Med · 2011
21.8 vs 20.3 monthsPFS (restricted mean at 36 months)
Clinical trial · Phase 3
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
N Engl J Med · 2011
10.3 monthsMedian PFS — control group
Clinical trial · Phase 3
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
N Engl J Med · 2010
0.98 (90% CI 0.84 to 1.13)Hazard ratio for death (neoadjuvant chemotherapy vs primary surgery)
Other
Development of an ovarian cancer symptom index
Cancer · 2007
Pelvic/abdominal pain, urinary frequency/urgency, increased abdominal size/bloating, difficulty eating/feeling fullSymptoms associated with ovarian cancer (when present for less than 1 year and occurring more than 12 days a month)
Clinical trial · Phase 3
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
JCO · 2003
20.7 months (carboplatin + paclitaxel) vs 19.4 months (cisplatin + paclitaxel)Median progression-free survival
Clinical trial · Phase 3
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
N Engl J Med · 1996
73% vs 60% (cisplatin-paclitaxel vs cisplatin-cyclophosphamide)Response rate (patients with measurable disease, 216 patients)
Clinical trial · Phase 3
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Annals of Oncology · 2024
1.01 (95% CI 0.84–1.23)Overall survival hazard ratio, overall population
Clinical trial · Phase 3
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
N Engl J Med · 2023
5.62 vs 3.98 monthsMedian progression-free survival
Clinical trial · Phase 3
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
N Engl J Med · 2019
21.9 vs 10.4 monthsMedian PFS in HRD-positive patients
Clinical trial · Phase 3
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
N Engl J Med · 2018
HR 0.66Risk of recurrence or death
Clinical trial · Phase 3
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
N Engl J Med · 2018
HR 0.30Risk of progression or death
Nothing found.